- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01621399
Safety and Efficacy Study to Treat Bacterial Vaginosis
August 20, 2013 updated by: Medicis Global Service Corporation
A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis
The purpose of this study is to determine if product 55394 is safe and efficacious for the treatment of bacterial vaginosis.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
651
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
-
California
-
La Mesa, California, United States
-
Los Angeles, California, United States
-
San Diego, California, United States
-
Torrance, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Connecticut
-
Groton, Connecticut, United States
-
-
Florida
-
Boyton Beach, Florida, United States
-
Clearwater, Florida, United States
-
Miami, Florida, United States
-
North Miami, Florida, United States
-
Sunrise, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
Augusta, Georgia, United States
-
Roswell, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Louisiana
-
Marrero, Louisiana, United States
-
-
Massachusetts
-
Falls River, Massachusetts, United States
-
-
Michigan
-
Detroit, Michigan, United States
-
Saginaw, Michigan, United States
-
-
Nebraska
-
Lincoln, Nebraska, United States
-
-
New Jersey
-
Lawrenceville, New Jersey, United States
-
Neptune, New Jersey, United States
-
Plainsboro, New Jersey, United States
-
-
Ohio
-
Columbus, Ohio, United States
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, United States
-
Philadelphia, Pennsylvania, United States
-
-
South Carolina
-
Columbia, South Carolina, United States
-
-
Tennessee
-
Jackson, Tennessee, United States
-
-
Texas
-
Corpus Christi, Texas, United States
-
Houston, Texas, United States
-
Schertz, Texas, United States
-
-
Vermont
-
Williston, Vermont, United States
-
-
Virginia
-
Virginia Beach, Virginia, United States
-
-
Washington
-
Seattle, Washington, United States
-
Tacoma, Washington, United States
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Have a clinical diagnosis of bacterial vaginosis as determined by the investigator.
- Other items as identified in the protocol.
Exclusion Criteria:
- Have a known or suspected other infectious cause of vulvovaginitis.
- Other items as identified in the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Vehicle
Treatment with the vehicle (placebo)
|
The vehicle vaginal gel in an applicator (placebo).
|
|
Experimental: Product 55394
Treatment with product 55394
|
Product 55394 vaginal gel in a prefilled applicator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical Cure
Time Frame: Day 21
|
The proportion of subjects with a clinical cure at the Day 21 visit, as assessed by the investigator.
|
Day 21
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Therapeutic Cure
Time Frame: Day 21
|
The proportion of subjects with a therapeutic cure at the Day 21 visit.
Therapeutic cure is defined as both a clinical cure and bacteriological cure as assessed by the investigator and the central laboratory, respectively.
|
Day 21
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Ron Staugaard, Medicis Pharmaceutical
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2012
Primary Completion (Actual)
October 1, 2012
Study Completion (Actual)
December 1, 2012
Study Registration Dates
First Submitted
June 14, 2012
First Submitted That Met QC Criteria
June 15, 2012
First Posted (Estimate)
June 18, 2012
Study Record Updates
Last Update Posted (Estimate)
August 21, 2013
Last Update Submitted That Met QC Criteria
August 20, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MP-1601-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.